JP2018529625A - 妊娠特異的糖タンパク質を含む組成物及びその使用方法 - Google Patents

妊娠特異的糖タンパク質を含む組成物及びその使用方法 Download PDF

Info

Publication number
JP2018529625A
JP2018529625A JP2017551585A JP2017551585A JP2018529625A JP 2018529625 A JP2018529625 A JP 2018529625A JP 2017551585 A JP2017551585 A JP 2017551585A JP 2017551585 A JP2017551585 A JP 2017551585A JP 2018529625 A JP2018529625 A JP 2018529625A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
peptide
seq
psg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017551585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529625A5 (enExample
Inventor
ガブリエラ ドゥヴェクスラー
ガブリエラ ドゥヴェクスラー
ハリー マレック
ハリー マレック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of JP2018529625A publication Critical patent/JP2018529625A/ja
Publication of JP2018529625A5 publication Critical patent/JP2018529625A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017551585A 2015-09-17 2016-09-16 妊娠特異的糖タンパク質を含む組成物及びその使用方法 Pending JP2018529625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219900P 2015-09-17 2015-09-17
US62/219,900 2015-09-17
PCT/US2016/052131 WO2017049082A2 (en) 2015-09-17 2016-09-16 Compositions comprising pregnancy specific glycoproteins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2018529625A true JP2018529625A (ja) 2018-10-11
JP2018529625A5 JP2018529625A5 (enExample) 2019-10-17

Family

ID=58289625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017551585A Pending JP2018529625A (ja) 2015-09-17 2016-09-16 妊娠特異的糖タンパク質を含む組成物及びその使用方法

Country Status (6)

Country Link
US (2) USRE50535E1 (enExample)
EP (1) EP3261722B1 (enExample)
JP (1) JP2018529625A (enExample)
AU (1) AU2016323769B2 (enExample)
CA (1) CA2981191C (enExample)
WO (1) WO2017049082A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514194A (ja) * 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 変形性関節症の治療に使用するためのｐｓｇ１

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022219008A1 (en) 2021-04-14 2022-10-20 University College Cork - National University Of Ireland, Cork Treatment of cerebrovascular events and neurological disorders
JP2025534040A (ja) 2022-10-14 2025-10-09 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 腱傷害の治療における使用のための胎盤発現タンパク質

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5169835A (en) 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
EP2473523A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALLESTEROS A ET AL.: "Induction and activation of latent transforming growth factor-β1 are carried out by two distinct do", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 7, JPN6020028483, 13 February 2015 (2015-02-13), pages 4422 - 4231, ISSN: 0004318644 *
BLOIS SM ET AL.: "Pregnancy-specific glycoprotein 1 (PSG1) activates TGF-β and prevents dextran sodium sulfate (DSS)-", MUCOSAL IMMUNOLOGY, vol. 7, no. 2, JPN6020028481, 2014, pages 348 - 358, ISSN: 0004517649 *
MOORE T ET AL.: "Pregnancy-specific glycoproteins: complex gene families regulating maternal-fetal interactions", THE INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, vol. 58, JPN6020028480, 2014, pages 273 - 280, ISSN: 0004318640 *
SU H ET AL.: "Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a", THE BRITISH JOURNAL OF DERMATOLOGY, vol. 158, no. 6, JPN6020028484, 2008, pages 1197 - 1209, ISSN: 0004517650 *
豊嶋 崇徳: "ＧＶＨＤ制御と移植免疫寛容誘導の展望", ＭＨＣ（日本組織適合性学会誌）, vol. 第１５巻，第１号, JPN6020028482, 2008, pages 9 - 26, ISSN: 0004318642 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514194A (ja) * 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 変形性関節症の治療に使用するためのｐｓｇ１

Also Published As

Publication number Publication date
WO2017049082A3 (en) 2017-05-04
US11007249B2 (en) 2021-05-18
EP3261722A2 (en) 2018-01-03
USRE50535E1 (en) 2025-08-19
AU2016323769B2 (en) 2022-05-26
EP3261722B1 (en) 2021-04-14
CA2981191A1 (en) 2017-03-23
AU2016323769A1 (en) 2017-10-19
US20180177844A1 (en) 2018-06-28
CA2981191C (en) 2022-09-13
WO2017049082A2 (en) 2017-03-23
EP3261722A4 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
KR102653758B1 (ko) 인터류킨-2/인터류킨-2 수용체 알파 융합 단백질 및 사용 방법
CA2337743C (en) Tumor antigen based on products of the tumor suppressor gene wt1
US9840545B2 (en) Fusion protein comprising interleukin-2 and interleukin-33
EP1942925B1 (en) Methods for fusion polypeptide delivery into a cell
USRE50535E1 (en) Compositions comprising pregnancy specific glycoproteins and methods of use thereof
EP1525221A1 (en) Conjugate of notch signalling pathway modulators and their use in medical treatment
JP7274472B2 (ja) 制御性ｔ細胞エピトープ
US20240226148A9 (en) Compounds for immunomodulation
US20120164101A1 (en) Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
JP7520365B2 (ja) 神経変性または神経炎症の治療または予防のための新規のｉｌ－４－／ｉｌ－１３－由来ペプチド化合物
IL293628A (en) Interleukin 2 chimeric structures
EP2931293B1 (en) Compositions and methods for regulating erythropoiesis
WO2001002003A1 (en) Method of treating psoriasis with il-15 antagonist
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
WO2021160170A1 (en) Methods of use of soluble cd24 for treating sars-cov-2 infection
EP3790571B1 (en) Peptides derived from oca-b for use in the treatment of autoimmune diseases and of leukemia
WO1998056819A1 (en) Methods of regulating t cell and macrophage cytokine production, function and pathogenicity
KR101739305B1 (ko) 릴랙신을 유효성분으로 포함하는 항원 제시 세포의 성숙화 유도용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180316

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210601